Turalio FDA Approval History
FDA Approved: Yes (First approved August 2, 2019)
Brand name: Turalio
Generic name: pexidartinib
Dosage form: Capsules
Company: Daiichi Sankyo Inc.
Treatment for: Tenosynovial Giant Cell Tumor
Last updated by Judith Stewart, BPharm on Jan 6, 2020.
Turalio (pexidartinib) is a kinase inhibitor indicated for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adults.
Development timeline for Turalio
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.